BioRestorative Therapies, Inc. BRTX

BRTX Company Overview

BioRestorative Therapies, Inc. (NASDAQ: BRTX) is a clinical-stage regenerative medicine and cell therapy company focused on developing biologic therapies for orthopedic conditions and metabolic disorders. The company operates within the biotechnology and regenerative medicine industries, with research centered on the therapeutic use of adult stem cells and cell-based products. Its primary development programs include BRTX-100, an autologous cell therapy candidate for chronic lumbar disc disease, and ThermoStem, a metabolic cell-based platform targeting obesity and related metabolic conditions through the use of brown adipose-derived stem cells.

The company traces its origins to earlier biotechnology and regenerative medicine initiatives before adopting the BioRestorative Therapies name and strategic focus on stem-cell-based therapeutics. Over time, the company transitioned from broader regenerative research activities toward a more concentrated clinical development model centered on orthopedic and metabolic disease indications. BioRestorative has positioned itself within a specialized niche of regenerative medicine by emphasizing proprietary cell processing technologies and minimally invasive therapeutic approaches designed to address conditions with limited long-term treatment alternatives.